

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2022/2023 influenza season

as of November 8, 2023

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	0	1 ^a (1.1%)	1 ^a (1.1%)	0	0	64 (100%)	9 ^b (1.6%)	0	0	0	0	321 (100%)	0	0	0	0	0
Number of viruses tested	69	93	93	61	61	64	578	319	319	319	319	321	50	48	48	48	48
Number of viruses reported	177						3,469						84				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.